Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Wound Healing Phase Mechanism Map

Wound healing has four overlapping phases. Tissue-repair peptide claims map onto specific phases — understanding the phase logic is the cleanest way to read combination-stack rationales.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Pathway background

Wound healing is the orchestrated cellular and biochemical response by which an injured tissue returns to mechanical and functional integrity. It proceeds through four overlapping phases that begin within seconds of injury and continue for months. Each phase has distinct cellular actors, cytokine drivers, and matrix-remodelling enzymes — and each offers a different opportunity for pharmacological intervention.

The phase model is the standard framing for tissue-repair pharmacology and explains the rationale for combining peptides that act at different time-points: an angiogenic accelerator (BPC-157) paired with a longer- timescale remodelling agent (TB-500), or a proliferation-phase modulator (GHK-Cu) layered with antimicrobial cover (LL-37). Whether the combined effect is genuinely additive or synergistic in humans is largely unstudied — see why synergy is assumed not demonstrated.

The four phases

  1. Hemostasis (minutes) — platelet aggregation, fibrin clot formation. Sets the platform for inflammation.
  2. Inflammation (hours to days) — neutrophil and macrophage recruitment, cytokine signalling, debris clearance. Defective inflammation prolongs healing; excessive inflammation causes scarring.
  3. Proliferation (days to weeks) — angiogenesis, fibroblast proliferation, granulation tissue, re-epithelialisation. The phase most-claimed for peptide intervention.
  4. Remodelling (weeks to months) — collagen reorganisation, type-III to type-I collagen conversion, scar maturation, recovery of tensile strength. Matrix metalloproteinases and lysyl oxidase are central.

Peptide claims by phase

  • BPC-157 — claimed to act primarily in the inflammation and early-proliferation phases via VEGFR2 and nitric-oxide signalling. Rodent studies emphasise rapid onset of angiogenic response.
  • TB-500 — claimed to act in proliferation and remodelling via actin sequestration and progenitor cell recruitment. Effects are described as having a longer tissue half-life than BPC-157's acute angiogenic phase.
  • GHK-Cu — claimed to support the remodelling phase via collagen and matrix-metalloproteinase modulation; also studied in cosmetic and dermal-repair contexts.
  • LL-37 — claimed to modulate the inflammation phase via TLR-9 engagement and antimicrobial action; provides infection cover during the vulnerable early phases.
  • KPV — claimed anti-inflammatory action via NF-κB modulation; dampens excessive inflammatory drive.

Evidence status

Preclinical: abundant rodent evidence for tissue-repair endpoints in tendon, ligament, gut and cutaneous models. Phase attribution is largely inferred from time-course studies rather than from dedicated mechanism-by-phase trials.

Human: minimal. Tissue-repair endpoints in animal models do not robustly translate to human clinical outcomes, and the clinical-trial infrastructure for unapproved peptides in tendinopathy or wound healing is sparse. Topical and intra-articular routes — when studied — produce different evidence than systemic injection routes.

Translation caveat: human wounds vary widely (acute vs chronic, sterile vs contaminated, well-perfused vs ischaemic). A rodent acute-injury model does not establish a peptide's utility in diabetic foot ulceration, post-surgical recovery, or sports injury. See animal vs human evidence.

Related glossary

Related on this site